Skip to main content
Erschienen in: Diabetologia 1/2023

06.10.2022 | CONSENSUS REPORT

Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association

verfasst von: Jennifer L. Sherr, Lutz Heinemann, G. Alexander Fleming, Richard M. Bergenstal, Daniela Bruttomesso, Hélène Hanaire, Reinhard W. Holl, John R. Petrie, Anne L. Peters, Mark Evans

Erschienen in: Diabetologia | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

A technological solution for the management of diabetes in people who require intensive insulin therapy has been sought for decades. The last 10 years have seen substantial growth in devices that can be integrated into clinical care. Driven by the availability of reliable systems for continuous glucose monitoring, we have entered an era in which insulin delivery through insulin pumps can be modulated based on sensor glucose data. Over the past few years, regulatory approval of the first automated insulin delivery (AID) systems has been granted, and these systems have been adopted into clinical care. Additionally, a community of people living with type 1 diabetes has created its own systems using a do-it-yourself approach by using products commercialised for independent use. With several AID systems in development, some of which are anticipated to be granted regulatory approval in the near future, the joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association has created this consensus report. We provide a review of the current landscape of AID systems, with a particular focus on their safety. We conclude with a series of recommended targeted actions. This is the fourth in a series of reports issued by this working group. The working group was jointly commissioned by the executives of both organisations to write the first statement on insulin pumps, which was published in 2015. The original authoring group was comprised by three nominated members of the American Diabetes Association and three nominated members of the European Association for the Study of Diabetes. Additional authors have been added to the group to increase diversity and range of expertise. Each organisation has provided a similar internal review process for each manuscript prior to submission for editorial review by the two journals. Harmonisation of editorial and substantial modifications has occurred at both levels. The members of the group have selected the subject of each statement and submitted the selection to both organisations for confirmation.
Literatur
6.
Zurück zum Zitat Fleming GA, Petrie JR, Bergenstal RM, Holl RW, Peters AL, Heinemann L (2020) Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetologia 63:229–241. https://doi.org/10.1007/s00125-019-05034-1CrossRef Fleming GA, Petrie JR, Bergenstal RM, Holl RW, Peters AL, Heinemann L (2020) Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetologia 63:229–241. https://​doi.​org/​10.​1007/​s00125-019-05034-1CrossRef
7.
Zurück zum Zitat Heinemann L, Fleming GA, Petrie JR, Holl RW, Bergenstal RM, Peters AL (2015) Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia 58:862–870. https://doi.org/10.1007/s00125-015-3513-zCrossRef Heinemann L, Fleming GA, Petrie JR, Holl RW, Bergenstal RM, Peters AL (2015) Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia 58:862–870. https://​doi.​org/​10.​1007/​s00125-015-3513-zCrossRef
8.
Zurück zum Zitat Petrie JR, Peters AL, Bergenstal RM, Holl RW, Fleming GA, Heinemann L (2017) Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia 60:2319–2328. https://doi.org/10.1007/s00125-017-4463-4CrossRef Petrie JR, Peters AL, Bergenstal RM, Holl RW, Fleming GA, Heinemann L (2017) Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia 60:2319–2328. https://​doi.​org/​10.​1007/​s00125-017-4463-4CrossRef
9.
21.
28.
Zurück zum Zitat Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV (2008) Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 31:934–939. https://doi.org/10.2337/dc07-1967CrossRef Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV (2008) Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 31:934–939. https://​doi.​org/​10.​2337/​dc07-1967CrossRef
29.
Zurück zum Zitat Palisaitis E, El Fathi A, von Oettingen JE, Haidar A, Legault L (2021) A meal detection algorithm for the artificial pancreas: a randomized controlled clinical trial in adolescents with type 1 diabetes. Diabetes Care 44:604–606. https://doi.org/10.2337/dc20-1232CrossRef Palisaitis E, El Fathi A, von Oettingen JE, Haidar A, Legault L (2021) A meal detection algorithm for the artificial pancreas: a randomized controlled clinical trial in adolescents with type 1 diabetes. Diabetes Care 44:604–606. https://​doi.​org/​10.​2337/​dc20-1232CrossRef
30.
Zurück zum Zitat Blauw H, Onvlee AJ, Klaassen M, van Bon AC, DeVries JH (2021) Fully closed loop glucose control with a bihormonal artificial pancreas in adults with type 1 diabetes: an outpatient, randomized, crossover trial. Diabetes Care 44:836–838. https://doi.org/10.2337/dc20-2106CrossRef Blauw H, Onvlee AJ, Klaassen M, van Bon AC, DeVries JH (2021) Fully closed loop glucose control with a bihormonal artificial pancreas in adults with type 1 diabetes: an outpatient, randomized, crossover trial. Diabetes Care 44:836–838. https://​doi.​org/​10.​2337/​dc20-2106CrossRef
58.
60.
Zurück zum Zitat Isganaitis E, Raghinaru D, Ambler-Osborn L, iDCL Trial Research Group et al (2021) Closed-loop insulin therapy improves glycemic control in adolescents and young adults: outcomes from the International Diabetes Closed-Loop Trial. Diabetes Technol Ther 23:342–349. https://doi.org/10.1089/dia.2020.0572CrossRef Isganaitis E, Raghinaru D, Ambler-Osborn L, iDCL Trial Research Group et al (2021) Closed-loop insulin therapy improves glycemic control in adolescents and young adults: outcomes from the International Diabetes Closed-Loop Trial. Diabetes Technol Ther 23:342–349. https://​doi.​org/​10.​1089/​dia.​2020.​0572CrossRef
62.
64.
67.
99.
Zurück zum Zitat Miller KM, Beck RW, Foster NC, Maahs DM (2020) HbA1c levels in type 1 diabetes from early childhood to older adults: a deeper dive into the influence of technology and socioeconomic status on HbA1c in the T1D Exchange Clinic Registry findings. Diabetes Technol Ther 22:645–650. https://doi.org/10.1089/dia.2019.0393CrossRef Miller KM, Beck RW, Foster NC, Maahs DM (2020) HbA1c levels in type 1 diabetes from early childhood to older adults: a deeper dive into the influence of technology and socioeconomic status on HbA1c in the T1D Exchange Clinic Registry findings. Diabetes Technol Ther 22:645–650. https://​doi.​org/​10.​1089/​dia.​2019.​0393CrossRef
105.
Zurück zum Zitat Braune K, Lal RA, Petruželková L, et al (2022) OPEN International Healthcare Professional Network and OPEN Legal Advisory Group. Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. Lancet Diabetes Endocrinol 10:58–74 Braune K, Lal RA, Petruželková L, et al (2022) OPEN International Healthcare Professional Network and OPEN Legal Advisory Group. Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. Lancet Diabetes Endocrinol 10:58–74
Metadaten
Titel
Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association
verfasst von
Jennifer L. Sherr
Lutz Heinemann
G. Alexander Fleming
Richard M. Bergenstal
Daniela Bruttomesso
Hélène Hanaire
Reinhard W. Holl
John R. Petrie
Anne L. Peters
Mark Evans
Publikationsdatum
06.10.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 1/2023
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-022-05744-z

Weitere Artikel der Ausgabe 1/2023

Diabetologia 1/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.